Companies / AstraZeneca
AstraZeneca
Company- Registered trials
- 4804
- Ongoing
- 837/ 17%
- Completed
- 3321
- Related drugs
- 22
- Related conditions
- 22
Clinical trial landscape
4804 registered studies reference this company or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Unknown | 1153 | 195 | 838 | |
| Phase 1 | 1101 | 80 | 883 | |
| Phase 3 | 927 | 212 | 632 | |
| Phase 2 | 921 | 215 | 519 | |
| Phase 4 | 355 | 19 | 274 | |
| Phase 1/2 | 142 | 68 | 48 | |
| Not applicable | 140 | 40 | 80 | |
| Phase 2/3 | 46 | 6 | 35 | |
| Early Phase 1 | 19 | 2 | 12 | |
| All phases | 4804 | 837 | 3321 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Recent developments
| Biotech Deal Boom, Regulatory Advances, and CRISPR Pipeline Progress | theglobeandmail.com ↗ | |
| FDA Grants Roxadustat Orphan Drug Designation for Myelodysplastic Syndromes | drugs.com ↗ | |
| Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations | biopharmadive.com ↗ | |
| AstraZeneca Deepens China Push With COPD Drug License, Lung Cancer Deal and $15bn Investment | pharma.economictimes.indiatimes.com ↗ | |
| Merck Strengthens Oncology Pipeline as Keytruda Faces 2028 Patent Expiry | theglobeandmail.com ↗ | |
| China Rises as Pharma R&D Powerhouse While India Pushes Innovation | pharmexec.com ↗ | |
| Hengrui Gets NMPA Nod for ADC Phase II Trial, Reports Positive Obesity Data | hcplive.com ↗ | |
| FDA Grants Rolling Review for QTORIN Rapamycin Amid Scrutiny of Expedited Pathways | pharmaphorum.com ↗ | |
| CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors | jamanetwork.com ↗ | |
| FDA Approves Breztri Aerosphere for Asthma; EU CHMP Recommends Trixeo | hcplive.com ↗ |
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.